

### Certificate of analysis

SFC856-03-07

Operator: Galbha Duggal Date: 13/08/2015

Supervisor: Zam Cader Date: 12/02/2016


Signature: Lade


## Source of fibroblasts and reprogramming information

- SF856 from Oxford University Hospitals, 07/05/2014
- Reprogrammed at UOXF WIMM
- Reprogrammed on 09/10/14 at passage 4
- Cytotune v2 WP3 SOP10


## Viability post-thaw and Morphology according to SOP19 passage 21

- Cell count immediately post-thaw 2.76 x 10<sup>6</sup>
- Viability immediately post-thaw 87%
- Photo at 24h & day 4 post-thaw (scale bar = 100μm):





# Sendai clearance: according to WP3 SOP15 undetectable at passage 21



+ control

SFC180-01-01

SFC856-03-07

SFC856-03-08

SFC856-03-04

Product sizes: Actin 92bp; SeV 181bp; SeV KOS 528bp; SeV-Myc 532bp; SeV-Klf 410bp;

# Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 21

Sample	Passage Number	Initials	Reading 1	Reading 2	Ratio/Status
+ ve control			63	4516	71.68
- ve control			96	68	0.71
SFC856-03-07	p21	GD	33	26	0.79

### Results mean


Ratio 0 - 0.999 negative for mycoplasma

Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

# Flow cytometric analysis according to WP3 SOP 20 and 21 passage 21

### Tra-1-60:



### **NANOG:**



## SNP analysis according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 21
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB